Does the sequence of high-dose rate brachytherapy boost and IMRT for prostate cancer impact early toxicity outcomes? Results from a single institution analysis-Reference-Cited by-同舟云学术

Does the sequence of high-dose rate brachytherapy boost and IMRT for prostate cancer impact early toxicity outcomes? Results from a single institution analysis

Published:2021-07 Issue: Volume:29 Page:47-53
ISSN:2405-6308
Container-title:Clinical and Translational Radiation Oncology
language:en
Short-container-title:Clinical and Translational Radiation Oncology

Author:

Roy Amit,Brenneman Randall J.,Hogan Jacob,Barnes Justin M.,Huang Yi,Morris Robert,Goddu Sreekrishna,Altman Michael,Garcia-Ramirez Jose,Li Harold,Zoberi Jacqueline E.,Bullock Arnold,Kim Eric,Smith Zachary,Figenshau Robert,Andriole Gerald L.,Baumann Brian C.,Michalski Jeff M.,Gay Hiram A.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference32 articles.

1. Favorable preliminary outcomes for men with low- and intermediate-risk prostate cancer treated with 19-Gy single-fraction high-dose-rate brachytherapy;Krauss;Int J Radiat Oncol Biol Phys,2017

2. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy;Morton;Radiother Oncol J Eur Soc Ther Radiol Oncol,2020

3. Ten-year survival after high-dose-rate brachytherapy combined with external beam radiation therapy in high-risk prostate cancer: a comparison with the Norwegian SPCG-7 cohort;Wedde;Radiother Oncol,2019

4. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer

5. High-dose-rate brachytherapy boost for prostate cancer treatment: different combinations of hypofractionated regimens and clinical outcomes;Vigneault;Radiother Oncol,2017